The Filings Report

Intuitive Surgical

ISRGNasdaqCIK 1035267Healthcare / Medical Devicesfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$3.0B
+21.7% on Q3 FY2025
Net income
$523M
−25.8% on Q3 FY2025
Free cash flow
$1.1B
+51.0% on Q3 FY2025
Diluted EPS
$1.49
−23.6% on Q3 FY2025
Revenue, TTM
$11.6B
trailing four quarters
Net margin, TTM
25.5%
net income $3.0B
Free cash flow, TTM
$3.6B
$4.1B less $492M capex
Cash and equivalents
$3.0B
long-term debt —, Sep 30, 2026
Shares, 12-month change
−2.2%
347M shares, Sep 30, 2026
Buybacks, TTM
$4.6B
3.1% of market value
Dividends, TTM
—
no yield
Market value
$149.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 21, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Intuitive Surgical reported revenue of $3.0B, +21.7% on Q3 FY2025, and net income of $523M (−25.8%). Operating margin was 19.4%. Free cash flow, operating cash flow less capital expenditures, was $1.1B ($1.2B less $113M). Diluted earnings per share were $1.49.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 21, 2026.

Revenue and net incomeRevenueNet income
$0$1B$2B$3B$4BQ4'22, Revenue: $1.7BQ4'22, Net income: $325MQ4'22Q1'23, Revenue: $1.7BQ1'23, Net income: $355MQ1'23Q2'23, Revenue: $1.8BQ2'23, Net income: $421MQ2'23Q3'23, Revenue: $1.7BQ3'23, Net income: $416MQ3'23Q4'23, Revenue: $1.9BQ4'23, Net income: $606MQ4'23Q1'24, Revenue: $1.9BQ1'24, Net income: $545MQ1'24Q2'24, Revenue: $2.0BQ2'24, Net income: $527MQ2'24Q3'24, Revenue: $2.0BQ3'24, Net income: $565MQ3'24Q4'24, Revenue: $2.4BQ4'24, Net income: $686MQ4'24Q1'25, Revenue: $2.3BQ1'25, Net income: $698MQ1'25Q2'25, Revenue: $2.4BQ2'25, Net income: $658MQ2'25Q3'25, Revenue: $2.5BQ3'25, Net income: $704MQ3'25Q4'25, Revenue: $2.9BQ4'25, Net income: $795MQ4'25Q1'26, Revenue: $2.8BQ1'26, Net income: $822MQ1'26Q2'26, Revenue: $2.9BQ2'26, Net income: $818MQ2'26Q3'26, Revenue: $3.0BQ3'26, Net income: $523MQ3'26$0$1B$2B$3B$4BQ4'22, Revenue: $1.7BQ4'22, Net income: $325MQ1'23, Revenue: $1.7BQ1'23, Net income: $355MQ1'23Q2'23, Revenue: $1.8BQ2'23, Net income: $421MQ3'23, Revenue: $1.7BQ3'23, Net income: $416MQ3'23Q4'23, Revenue: $1.9BQ4'23, Net income: $606MQ1'24, Revenue: $1.9BQ1'24, Net income: $545MQ1'24Q2'24, Revenue: $2.0BQ2'24, Net income: $527MQ3'24, Revenue: $2.0BQ3'24, Net income: $565MQ3'24Q4'24, Revenue: $2.4BQ4'24, Net income: $686MQ1'25, Revenue: $2.3BQ1'25, Net income: $698MQ1'25Q2'25, Revenue: $2.4BQ2'25, Net income: $658MQ3'25, Revenue: $2.5BQ3'25, Net income: $704MQ3'25Q4'25, Revenue: $2.9BQ4'25, Net income: $795MQ1'26, Revenue: $2.8BQ1'26, Net income: $822MQ1'26Q2'26, Revenue: $2.9BQ2'26, Net income: $818MQ3'26, Revenue: $3.0BQ3'26, Net income: $523MQ3'26

Net income losses drawn in red.

Free cash flow
−$500M$0$500M$1.0B$1.5BQ4'22, Free cash flow: $299MQ4'22Q1'23, Free cash flow: $177MQ1'23Q2'23, Free cash flow: $487MQ2'23Q3'23, Free cash flow: $292MQ3'23Q4'23, Free cash flow: −$207MQ4'23Q1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $311MQ2'24Q3'24, Free cash flow: $459MQ3'24Q4'24, Free cash flow: $511MQ4'24Q1'25, Free cash flow: $465MQ1'25Q2'25, Free cash flow: $560MQ2'25Q3'25, Free cash flow: $736MQ3'25Q4'25, Free cash flow: $730MQ4'25Q1'26, Free cash flow: $809MQ1'26Q2'26, Free cash flow: $948MQ2'26Q3'26, Free cash flow: $1.1BQ3'26−$500M$0$500M$1.0B$1.5BQ4'22, Free cash flow: $299MQ1'23, Free cash flow: $177MQ1'23Q2'23, Free cash flow: $487MQ3'23, Free cash flow: $292MQ3'23Q4'23, Free cash flow: −$207MQ1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $311MQ3'24, Free cash flow: $459MQ3'24Q4'24, Free cash flow: $511MQ1'25, Free cash flow: $465MQ1'25Q2'25, Free cash flow: $560MQ3'25, Free cash flow: $736MQ3'25Q4'25, Free cash flow: $730MQ1'26, Free cash flow: $809MQ1'26Q2'26, Free cash flow: $948MQ3'26, Free cash flow: $1.1BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $1.6BQ4'22Q1'23, Cash and equivalents: $2.1BQ1'23Q2'23, Cash and equivalents: $3.4BQ2'23Q3'23, Cash and equivalents: $3.6BQ3'23Q4'23, Cash and equivalents: $2.8BQ4'23Q1'24, Cash and equivalents: $2.8BQ1'24Q2'24, Cash and equivalents: $3.0BQ2'24Q3'24, Cash and equivalents: $2.4BQ3'24Q4'24, Cash and equivalents: $2.0BQ4'24Q1'25, Cash and equivalents: $2.6BQ1'25Q2'25, Cash and equivalents: $3.4BQ2'25Q3'25, Cash and equivalents: $2.8BQ3'25Q4'25, Cash and equivalents: $3.4BQ4'25Q1'26, Cash and equivalents: $2.0BQ1'26Q2'26, Cash and equivalents: $2.8BQ2'26Q3'26, Cash and equivalents: $3.0BQ3'26$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $1.6BQ1'23, Cash and equivalents: $2.1BQ1'23Q2'23, Cash and equivalents: $3.4BQ3'23, Cash and equivalents: $3.6BQ3'23Q4'23, Cash and equivalents: $2.8BQ1'24, Cash and equivalents: $2.8BQ1'24Q2'24, Cash and equivalents: $3.0BQ3'24, Cash and equivalents: $2.4BQ3'24Q4'24, Cash and equivalents: $2.0BQ1'25, Cash and equivalents: $2.6BQ1'25Q2'25, Cash and equivalents: $3.4BQ3'25, Cash and equivalents: $2.8BQ3'25Q4'25, Cash and equivalents: $3.4BQ1'26, Cash and equivalents: $2.0BQ1'26Q2'26, Cash and equivalents: $2.8BQ3'26, Cash and equivalents: $3.0BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Intuitive Surgical income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 21, 2026Q2 FY2026ended Jun 30, 2026filed Jul 21, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 3, 2026Q3 FY2025ended Sep 30, 2025filed Oct 22, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 23, 2025Q4 FY2024ended Dec 31, 2024filed Jan 31, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue3,0492,8922,7712,8662,5052,4402,2532,414+21.7%
Cost of revenue964932940962843822796771+14.4%
Gross profit2,0841,9601,8311,9041,6621,6181,4581,642+25.4%
Research and development408371362353329313316295+24.0%
Selling, general and administrative633618613687573561563613+10.5%
Operating income593972855864760743578735−22.0%
Other income (expense)7683859196899075−20.6%
Pretax income6681,055940956855832669810−21.8%
Income tax144231114156146168(35)122−1.4%
Net income523818822795704658698686−25.8%
Diluted EPS ($)1.492.292.28—1.951.811.92—−23.6%
Diluted shares (millions)352357360—362364365——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Intuitive Surgical balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 21, 2026Q2 FY2026ended Jun 30, 2026filed Jul 21, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 3, 2026Q3 FY2025ended Sep 30, 2025filed Oct 22, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 23, 2025Q4 FY2024ended Dec 31, 2024filed Jan 31, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents2,9782,7602,0073,3682,8073,4032,5742,027+6.1%
Short-term investments1,0642,4562,5112,5672,1021,9231,9381,986−49.4%
Total current assets8,4289,5438,8109,7808,5258,7467,6587,111−1.1%
Total assets19,34920,87720,11120,45919,35220,16319,22018,743−0.0%
Total current liabilities2,5331,9231,9112,0061,8031,6931,5381,745+40.5%
Long-term debt—————————
Total liabilities3,2312,5792,5142,5172,3102,2102,0132,214+39.9%
Stockholders’ equity15,98618,16817,47517,82416,93017,84617,10616,434−5.6%
Shares outstanding (millions)347353354355354358358357—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Intuitive Surgical cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 21, 2026Q2 FY2026ended Jun 30, 2026filed Jul 21, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 3, 2026Q3 FY2025ended Sep 30, 2025filed Oct 22, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 23, 2025Q4 FY2024ended Dec 31, 2024filed Jan 31, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow1,2241,061912893841715582823+45.6%
Capital expenditures113113103163105155117312+7.3%
Free cash flow (CFO − capex)1,111948809730736560465511+51.0%
Depreciation and amortization—————————
Share repurchases2,9763201,1232011,91318100+55.5%
Dividends paid————0————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 3, 2026.

Income statement

Intuitive Surgical income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 3, 2026FY2024ended Dec 31, 2024filed Jan 31, 2025FY2023ended Dec 31, 2023filed Jan 31, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 3, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 4, 2019FY2017ended Dec 31, 2017filed Feb 2, 2018FY2016ended Dec 31, 2016filed Feb 6, 2017FY2015ended Dec 31, 2015filed Feb 2, 2016FY2014ended Dec 31, 2014filed Feb 6, 2015FY2013ended Dec 31, 2013filed Feb 3, 2014FY2012ended Dec 31, 2012filed Feb 4, 2013FY2011ended Dec 31, 2011filed Feb 6, 2012FY2010ended Dec 31, 2010filed Feb 1, 2011FY2009ended Dec 31, 2009filed Jan 29, 2010FY2008ended Dec 31, 2008filed Jul 23, 2009FY2007ended Dec 31, 2007filed Jul 23, 2009
Revenue10,0658,3527,1246,2225,7104,3584,4793,7243,1382,7072,3842,1322,2652,1791,7571,4131,052875601
Cost of revenue3,4222,7182,3952,0261,7521,4971,3681,120936814807718671609484383301254187
Gross profit6,6425,6344,7304,1963,9592,8613,1102,6042,2021,8931,5781,4141,5941,5701,2741,030751621414
Research and development1,3121,145999879671595557418329240197178168170140116957949
Selling, general and administrative2,3852,1401,9641,7401,4671,2161,178987811704641691574522439359279231159
Operating income2,9462,3491,7671,5771,8211,0501,3751,1991,063950740545853878695555377311207
Other income (expense)366325192306915712880423619418161517192430
Pretax income3,3112,6741,9591,6071,8901,2071,5021,2801,105985759549871894710572396335237
Income tax43533614226216214012015543424717013020023721519116413193
Net income2,8562,3231,7981,3221,7051,0611,3791,128671738589419671657495382233204145
Diluted EPS ($)7.876.425.033.654.662.943.853.16*1.92*2.09*1.73*1.23*1.86*1.78*1.37*1.05*0.66*0.57*0.41*
Diluted shares (millions)363362357362366361358356*349*354*341*339*361*370*362*363*353*359*351*

Balance sheet

Intuitive Surgical balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 3, 2026FY2024ended Dec 31, 2024filed Jan 31, 2025FY2023ended Dec 31, 2023filed Jan 31, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 3, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 4, 2019FY2017ended Dec 31, 2017filed Feb 2, 2018FY2016ended Dec 31, 2016filed Feb 6, 2017FY2015ended Dec 31, 2015filed Feb 2, 2016FY2014ended Dec 31, 2014filed Feb 6, 2015FY2013ended Dec 31, 2013filed Feb 3, 2014FY2012ended Dec 31, 2012filed Feb 4, 2013FY2011ended Dec 31, 2011filed Feb 6, 2012FY2010ended Dec 31, 2010filed Feb 1, 2011FY2009ended Dec 31, 2009filed Jan 29, 2010FY2008ended Dec 31, 2008filed Jul 23, 2009FY2007ended Dec 31, 2007filed Jul 23, 2009
Cash and equivalents3,3682,0272,7501,5811,2911,6231,1688586481,037715600782554466280221195123
Short-term investments2,5671,9862,4732,5372,9133,4892,0542,2051,3121,518845632621771563631334257—
Total current assets9,7807,1117,8886,2535,8456,6264,6634,3332,8093,2502,1961,8121,9321,8931,4661,276847704—
Total assets20,45918,74315,44212,97413,55511,1699,7337,8475,7776,4874,9073,9593,9504,0593,0632,3901,8101,475—
Total current liabilities2,0061,7451,6591,4221,1509651,030821663597492501381402321274203165—
Long-term debt———————————————————
Total liabilities2,5172,2142,0441,8611,6041,4101,4491,159996709588580449479418353272208—
Stockholders’ equity17,82416,43413,30811,04211,9019,7328,2646,6794,7795,7784,3203,3793,5013,5802,6462,0371,5371,267889
Shares outstanding (millions)355357352350358353*348*343*337*349*336*329*344*361*354*350*347*——

Cash flow statement

Intuitive Surgical cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 3, 2026FY2024ended Dec 31, 2024filed Jan 31, 2025FY2023ended Dec 31, 2023filed Jan 31, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 3, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 7, 2020FY2018ended Dec 31, 2018filed Feb 4, 2019FY2017ended Dec 31, 2017filed Feb 2, 2018FY2016ended Dec 31, 2016filed Feb 6, 2017FY2015ended Dec 31, 2015filed Feb 2, 2016FY2014ended Dec 31, 2014filed Feb 6, 2015FY2013ended Dec 31, 2013filed Feb 3, 2014FY2012ended Dec 31, 2012filed Feb 4, 2013FY2011ended Dec 31, 2011filed Feb 6, 2012FY2010ended Dec 31, 2010filed Feb 1, 2011FY2009ended Dec 31, 2009filed Jan 29, 2010FY2008ended Dec 31, 2008filed Jul 23, 2009FY2007ended Dec 31, 2007filed Jul 23, 2009
Operating cash flow3,0312,4151,8141,4912,0891,4851,5981,1701,1441,087806665880814678546392278206
Capital expenditures5401,1111,064532340342426187191548110610511483965310624
Free cash flow (CFO − capex)2,4911,3047509581,7501,1431,1739829531,033725560775700595450339172182
Depreciation and amortization———————————————————
Share repurchases2,29504162,607013427002,274431841,0001,10923833219915000
Dividends paid———————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$17M
22 sales by 7 insiders; officers and directors $17M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$69M
81 sales by 11 insiders; officers and directors $69M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 28, 2026Brosius MarkEVP & Chief Mfg and Supply Chaopen-market sale10b5-161$441.60$27K581Oct 28, 2026
Oct 27, 2026Brosius MarkEVP & Chief Mfg and Supply Chaopen-market sale10b5-161$451.63$28K642Oct 28, 2026
Oct 26, 2026Brosius MarkEVP & Chief Mfg and Supply Chaopen-market sale10b5-161$451.75$28K703Oct 28, 2026
Oct 23, 2026Barratt Craig HDirectoroption exercise1,150$90.49$104K1,150Oct 26, 2026
Oct 23, 2026Barratt Craig HDirectoropen-market sale10b5-11,150$443.80$510K0Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise307$304.67$94K1,333Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise307$229.39$70K1,640Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise312$290.33$91K1,952Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise406$347.42$141K2,358Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise406$245.60$100K2,764Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise567$242.34$137K3,331Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise567$177.99$101K3,898Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise262$166.62$44K4,160Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise263$182.83$48K4,423Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise325$174.26$57K4,748Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleroption exercise325$139.52$45K5,073Oct 26, 2026
Oct 23, 2026Widman FredrikVP Corporate Controlleropen-market sale10b5-14,047$453.21$2M1,026Oct 26, 2026
Oct 23, 2026Wadors Patricia LSVP Chief Human Resources Offiopen-market sale10b5-11,078$443.80$478K0Oct 26, 2026
Oct 23, 2026Guthart Gary SDirectoropen-market sale10b5-1indirect20,095$451.61$9M1MOct 26, 2026
Oct 10, 2026Wadors Patricia LSVP Chief Human Resources Offioption exercise2,140$0.00—2,140Oct 13, 2026
Oct 10, 2026Wadors Patricia LSVP Chief Human Resources Offitax withholding1,062$423.96$450K1,078Oct 13, 2026
Oct 10, 2026Loeb GaryEVP & Chief Legal and Complianoption exercise2,612$0.00—7,932Oct 13, 2026
Oct 10, 2026Loeb GaryEVP & Chief Legal and Compliantax withholding1,296$423.96$549K6,636Oct 13, 2026
Sep 15, 2026Widman FredrikVP Corporate Controlleroption exercise546$79.64$43K1,572Sep 16, 2026
Sep 15, 2026Widman FredrikVP Corporate Controlleropen-market sale10b5-1546$374.44$204K1,026Sep 16, 2026

Full insider history for Intuitive Surgical, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held ISRG in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded ISRG by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$37M93,9270.06%trimmed −3.5%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Intuitive Surgical, Inc., CIK 1035267 on EDGAR
Extract generated
October 22, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: capex FY2011
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 22, 2026.

JSON file
/data/financials/ISRG.json